Back to Search
Start Over
Immunotherapeutic potential of collagen V oral administration in mBSA/CFA-induced arthritis.
- Source :
-
PloS one [PLoS One] 2024 Oct 08; Vol. 19 (10), pp. e0311263. Date of Electronic Publication: 2024 Oct 08 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- We hypothesized that after synovial injury, collagen V (Col V) expose occult antigens, and Col V autoantibodies develop, indicating the loss of immune tolerance against this molecule, thus leading to damage to mesenchymal-derived cells as well as the extracellular matrix in experimental arthritis. Thus, the present study investigated the effects of oral administration of Col V on the synovium after the development of inflammation in mBSA/CFA-induced arthritis. After fourteen days of intraarticular administration of mBSA, 10 male Lewis rats were orally administered Col V (500 μg/300 μL) diluted in 0.01 N acetic acid (IA-Col V group). The arthritic group (IA group, n = 10) received only intraarticular mBSA. An intra-articular saline injection (20 μL) was given to the control group (CT-Col V, n = 5). IA group presented damaged synovia, the expansion of the extracellular matrix by cellular infiltrate, which was characterized by T and B lymphocytes, and fibroblastic infiltration. In contrast, after Col V oral immunotherapy IA-Col V group showed a significant reduction in synovial inflammation and intense expression of IL-10+ and FoxP3+ cells, in addition to a reduction in Col V and an increase in Col I in the synovia compared to those in the IA group. Furthermore, an increase in IL-10 production was detected after IA-Col V group spleen cell stimulation with Col V in vitro. PET imaging did not differ between the groups. The evaluation of oral treatment with Col V, after mBSA/CFA-induced arthritis in rats, protects against inflammation and reduces synovial tissue damage, through modulation of the synovial matrix, showing an immunotherapeutic potential in inhibiting synovitis.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright: © 2024 Ramos da Silveira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Subjects :
- Animals
Male
Administration, Oral
Rats
Freund's Adjuvant administration & dosage
Immunotherapy methods
Interleukin-10
Forkhead Transcription Factors metabolism
Serum Albumin, Bovine
Arthritis, Experimental immunology
Arthritis, Experimental drug therapy
Arthritis, Experimental pathology
Rats, Inbred Lew
Synovial Membrane immunology
Synovial Membrane pathology
Collagen Type V immunology
Collagen Type V administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 19
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 39378196
- Full Text :
- https://doi.org/10.1371/journal.pone.0311263